Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Soligenix ( (SNGX) ) has shared an update.
On April 28, 2026, Soligenix reported interim results from its pivotal Phase 3 FLASH2 trial of HyBryte in CTCL, with an independent Data Monitoring Committee recommending the study be halted for futility after 18 weeks of treatment failed to reproduce the efficacy signal seen in the prior FLASH study. The company, which has approximately $5.9 million in cash, said it will analyze the FLASH2 dataset to understand the disappointing outcome and assess whether any patient subgroups might still benefit from HyBryte, while concurrently evaluating strategic options such as potential M&A and advancing its orphan-designated dusquetide program in Behçet’s disease, moves that could significantly reshape its development pipeline and capital priorities.
The most recent analyst rating on (SNGX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Soligenix stock, see the SNGX Stock Forecast page.
Spark’s Take on SNGX Stock
According to Spark, TipRanks’ AI Analyst, SNGX is a Neutral.
The score is held down primarily by weak financial performance: minimal revenue, widening losses, and sustained cash burn that imply continued reliance on financing. Technicals are neutral-to-slightly bearish with the stock below key moving averages. Corporate updates provide a modest positive catalyst (Phase 3 progress and near-term milestones), but dilution risk from financing tools and the lack of profitable operations keep the overall score below average.
To see Spark’s full report on SNGX stock, click here.
More about Soligenix
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with significant unmet medical need. Its lead programs have included HyBryte, a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL), and dusquetide, which is being explored for inflammatory indications such as Behçet’s disease, with a strategic emphasis on orphan and specialty markets.
Average Trading Volume: 236,472
Technical Sentiment Signal: Sell
Current Market Cap: $14.33M
For a thorough assessment of SNGX stock, go to TipRanks’ Stock Analysis page.